1-[(Tert-butoxy)carbonyl]piperidine-2-carboxylic acid → 1-(3,4-Dimethoxyphenyl)-4-(octahydropyrido[1,2-a]pyrazin-2-yl)butane-1,4-dione
反応式
[CH3:1][O:2][C:3]1[CH:4]=[C:5]([C:11](=[O:25])[CH2:12][CH2:13][C:14]([N:16]2[CH2:21][CH2:20][N:19]3[CH2:22][CH2:23][CH2:24][C@H:18]3[CH2:17]2)=[O:15])[CH:6]=[CH:7][C:8]=1[O:9][CH3:10].[C:26](OC(N1CCCCC1C(O)=O)=O)(C)(C)C>>[CH3:1][O:2][C:3]1[CH:4]=[C:5]([C:11](=[O:25])[CH2:12][CH2:13][C:14]([N:16]2[CH2:21][CH2:20][N:19]3[CH2:26][CH2:22][CH2:23][CH2:24][CH:18]3[CH2:17]2)=[O:15])[CH:6]=[CH:7][C:8]=1[O:9][CH3:10]参加物
3
実験手順
360 mg of the title compound were prepared as described for 1-(3,4-dimethoxyphenyl)-4-((S)-hexahydropyrrolo[1,2-a]pyrazin-2-yl)butane-1,4-dione, using 1-(tert-butoxycarbonyl)piperidine 2 carboxylic acid instead of BOC-protected proline.
出典と根拠
- ORDレコード
- ord-2cc171183a1c47cf871fd993800e89ed
- 出典データセット
- uspto-grants-2007_03
- DOI